KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$304.0 million.

  • Pfizer's Net Cash Flow rose 8240.74% to -$304.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.0 million, marking a year-over-year increase of 10662.09%. This contributed to the annual value of -$1.7 billion for FY2024, which is 17009.65% down from last year.
  • According to the latest figures from Q3 2025, Pfizer's Net Cash Flow is -$304.0 million, which was up 8240.74% from $173.0 million recorded in Q2 2025.
  • Pfizer's Net Cash Flow's 5-year high stood at $1.8 billion during Q2 2023, with a 5-year trough of -$2.1 billion in Q1 2024.
  • Its 5-year average for Net Cash Flow is -$10.9 million, with a median of $266.5 million in 2024.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 672500.0% in 2022, then tumbled by 40584.07% in 2024.
  • Over the past 5 years, Pfizer's Net Cash Flow (Quarter) stood at $568.0 million in 2021, then plummeted by 189.26% to -$507.0 million in 2022, then surged by 38.07% to -$314.0 million in 2023, then plummeted by 450.32% to -$1.7 billion in 2024, then soared by 82.41% to -$304.0 million in 2025.
  • Its Net Cash Flow stands at -$304.0 million for Q3 2025, versus $173.0 million for Q2 2025 and $382.0 million for Q1 2025.